Large gap with delayed quotes
|
Last quote
01/15/2026
-
15:40:44
|
Bid
01/15/2026 -
15:40:44
|
Bid Volume |
Ask
01/15/2026 -
15:40:44
|
Ask Volume |
|---|---|---|---|---|
|
55.70
-0.90
(
-1.59% )
|
55.60
|
200 |
55.80
|
372 |
Analysis date: 13.01.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 13.01.2026.
Interest
Weak
Weak
Two stars since 13.01.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 09.01.2026 at a price of 58.00.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, we believe the share price is currently fairly priced.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 25.11.2025.
4wk Rel Perf
-4.26%
-4.26%
The four-week dividend-adjusted underperformance versus STOXX600 is 4.26%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 13.01.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.30%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.72%.
Mkt Cap in $bn
0.84
0.84
With a market capitalization <$2bn, BASILEA PHARMACEUTIC is considered a small-cap stock.
G/PE Ratio
0.91
0.91
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
14.87
14.87
The estimated PE is for the year 2027.
LT Growth
13.58%
13.58%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
3
3
Over the last seven weeks, an average of 3 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
104
104
For 1% of index variation, the stock varies on average by 1.04%.
Correlation
0.43
0.43
43.03% of stock movements are explained by index variations.
Value at Risk
10.51
10.51
The value at risk is estimated at CHF 10.51. The risk is therefore 19.42%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
12.11.2004
12.11.2004